MUC4 and paroxysmal nocturnal hemoglobinuria: On this basis, we hypothesise that for PNH patients with concurrent MUC4 mutations, early complement inhibitor initiation (where available) or prophylactic LMWH (for those unable to access complement inhibitors) could be potential strategies for primary TE prevention – although bleeding risk post‐anticoagulation must be closely monitored.